Edison issues report on BB Biotech (BION)
BB Biotech AG
WKN: A0NFN3 / Name: BB Biotech / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
59,60 €
-0,17 %
Alnylam reported that the benefits of treatment were consistent across major sub-groups of trial participants, with adverse events and geometry dash side-effects leading to study discontinuation similar for those given the drug and those given a placebo.
Neueste Beiträge
BennieRichards in Global Customer Engagement Review from Braze Finds Marketers are Prioritizing Increased Investments in Customer Retention, Braze Inc.